AI assistant
NEOGENOMICS INC — Director's Dealing 2025
May 13, 2025
32227_dirs_2025-05-13_66799561-e653-45dc-abc4-a9ac0cf043e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2025-05-11
Reporting Person: Olivo Alicia C (EVP, GC & Business Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-11 | Common Stock | M | 6503 | — | Acquired | 51204 | Direct |
| 2025-05-11 | Common Stock | F | 1584 | — | Disposed | 49620 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-11 | Restricted Stock Unit | $0 | M | 6503 | Disposed | Common Stock (6503) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $19.12 | 2026-09-30 | Common Stock (1046) | 1046 | Direct |
| Stock Option (Right to Buy) | $27.34 | 2027-05-01 | Common Stock (1024) | 1024 | Direct |
| Stock Option (Right to Buy) | $48.99 | 2028-05-01 | Common Stock (516) | 516 | Direct |
| Stock Option (Right to Buy) | $46.10 | 2028-08-01 | Common Stock (1117) | 1117 | Direct |
| Stock Option (Right to Buy) | $9.45 | 2029-05-01 | Common Stock (22222) | 22222 | Direct |
| Stock Option (Right to Buy) | $10.05 | 2029-09-01 | Common Stock (55332) | 55332 | Direct |
| Stock Option (Right to Buy) | $19.65 | 2030-05-11 | Common Stock (36508) | 36508 | Direct |
| Performance Stock Unit | $0 | Common Stock (19508) | 19508 | Direct | |
| Stock Option (Right to Buy) | $16.45 | 2034-02-23 | Common Stock (42344) | 42344 | Direct |
| Performance Stock Unit | $0 | Common Stock (25330) | 25330 | Direct | |
| Restricted Stock Unit | $0 | Common Stock (59382) | 59382 | Direct | |
| Restricted Stock Unit | $0 | Common Stock (16886) | 16886 | Direct | |
| Stock Option (Right to Buy) | $13.05 | 2035-02-21 | Common Stock (107450) | 107450 | Direct |
| Restricted Stock Unit | $0 | Common Stock (63238) | 63238 | Direct |
Footnotes
F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
F2: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F3: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F4: Once vested, the shares of common stock are not subject to expiration.
F5: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F10: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F11: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F12: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F13: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F14: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F15: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F16: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F17: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F18: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.